Transcenta Debuts Encouraging Phase II Data from First-line Triple Combo Trial of Osemitamab (TST001) for G/GEJ Cancer at ASCO 2024

/PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a global clinical stage biopharmaceutical company with fully-integrated capabilities...

Related Keywords

China ,Shanghai ,Guangzhou ,Guangdong ,Hangzhou ,Zhejiang ,Princeton ,Massachusetts ,United States ,Boston ,Beijing ,Suzhou ,Jiangsu ,Los Angeles ,Product Development Center ,Prnewswire Transcenta Holding Limited ,Transcenta Immune Tolerance Breaking Technology ,Clinical Development Centers In Princeton ,Group Headquarters ,Translational Research Center ,Holding Limited ,Clinical Oncology Volume ,Immune Tolerance Breaking Technology ,Orphan Drug Designation ,Manufacturing Facility ,Clinical Development Centers ,External Partnering Center ,Suzhou Industrial ,